slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2.260 KRW | +1,12% | +2,96% | -33,14% |
Vakgebied
Verkoop per activiteit
KRW in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
T-cell Therapy and Antibody Therapeutics
100,0
%
| 216 | 100,0 % | 132 | 100,0 % | -38,95% |
Verkoop per regio
KRW in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
South Korea
70,1
%
| 216 | 100,0 % | 92 | 70,1 % | -57,18% |
China
29,9
%
| - | - | 39 | 29,9 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Soo-Young Choi
CEO | Chief Executive Officer | 63 | 01-03-20 |
Byoung Kwon
FOU | Founder | 77 | 27-02-15 |
Guk-Hee Lee
AUD | Comptroller/Controller/Auditor | 76 | 01-12-16 |
Young-Ho Kim
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Yong-Sang Cho
BRD | Director/Board Member | 76 | 28-12-18 |
Byoung Kwon
FOU | Founder | 77 | 27-02-15 |
Myung-Hee Han
BRD | Director/Board Member | 76 | 28-12-18 |
Young-Ho Kim
PRN | Corporate Officer/Principal | - | - |
Bin Heo
BRD | Director/Board Member | 48 | - |
Jang-Woo Park
BRD | Director/Board Member | 75 | 01-03-18 |
Soo-Young Choi
CEO | Chief Executive Officer | 63 | 01-03-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 47 471 | 0 | 2 ( 0,004213 %) | 70,41 % |
Aandeel B | 1 | 36 762 855 | 25 884 960 ( 70,41 %) | 3 975 ( 0,0108 %) |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
EUTILEX.CO.,LTD 0.01% | 3 977 | 0.01% | 6 359 $ |
Bedrijfsgegevens
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
-33,14% | 60,88 mln. | |
-1,26% | 89,46 mld. | |
+2,76% | 40,74 mld. | |
-9,01% | 33,03 mld. | |
+55,32% | 24,68 mld. | |
-16,44% | 15,12 mld. | |
-9,05% | 12,81 mld. | |
-12,11% | 11,79 mld. | |
-43,61% | 11,64 mld. | |
+7,79% | 8,9 mld. |
- Beurs
- Aandelen
- Koers A263050
- Onderneming Eutilex.Co.,Ltd